on IKONISYS (EPA:ALIKO)
Hospitex International Initiates Urine24 Feasibility Study in Uzbekistan
Aliko Scientific's subsidiary, Hospitex International, has signed a preliminary agreement with Uzbekistan's Jizzakh Oncology Institute. This partnership launches a feasibility study for a national Urine24 screening project, focusing on urinary tract cancer detection. The agreement highlights Urine24's international appeal and Aliko Scientific's prowess in large-scale oncology diagnostics.
The feasibility study will scrutinize technical, operational, regulatory, financial, and organizational criteria for the potential program. Additionally, it includes workflow analysis, laboratory assessments, and regulatory reviews. An operational document will guide further discussion and potential program structuring.
The initial implementation phase, contingent upon positive study outcomes, could reach an estimated value of €1 million. This collaboration follows a Health Study Tour led by the Italian Trade Agency. The project leverages the Urine24 model, designed for scalable implementation in varied healthcare infrastructures.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IKONISYS news